Savara Inc. (SVRA)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 70
- Market Cap
- $1.1B
About Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
SentiSense also tracks daily options readings for Savara Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Savara Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.